Costs and benefits of different strategies to screen for cervical cancer in less-developed countries

Journal of the National Cancer Institute

Volumn 94, Issue 19, 2002, Pages 1469-1483

  Mandelblatt, Jeanne S ^a,g   Lawrence, William F ^a   Gaffikin, Lynne ^b   Limpahayom, Khunying Kobchitt ^c   Lumbiganon, Pisake ^d   Warakamin, Suwanna ^e   King, Jason ^a   Yi, Bin ^a   Ringers, Patricia ^b   Blumenthal, Paul D ^f  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b JHPIEGO   (United States)

^c Royal Thai College of Obstetricians and Gynaecologists   (Thailand)

^d KHON KAEN UNIVERSITY   (Thailand)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DEVELOPING COUNTRY; FEMALE; FOLLOW UP; GYNECOLOGICAL EXAMINATION; HEALTH CARE POLICY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; INTERMETHOD COMPARISON; LASER SURGERY; LIFE EXPECTANCY; MEDICAL DECISION MAKING; PAPANICOLAOU TEST; POPULATION RESEARCH; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SIMULATION; THAILAND; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS IDENTIFICATION; WART VIRUS;

EID: 0037009835     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.19.1469     Document Type: Article

References (121)

1. National Cancer Institute. Surveillance Epidemiology and End-Results. Washington (DQ: Department of Health and Human Services; 1998.
2. Ferlay J, Parkin DM, Pisani P. Cancer incidence and mortality worldwide. IARC; 2000.
3. Martin N, Srisukho S, Kunpradist 0, SuttaJit M. Cancer survival in Chiang Mai, Thailand. IARC Sci Publ 1998;(145):109-21.
4. Boon ME, Schwinghammer H, van der Veen G. Analysis of lifestyle data and cytologic findings in a pilot cervical screening project in rural Vietnam. Acta Cytol 1999;43:786-93.
5. Parkin DM. Cancer in developing countries. Cancer Surv 1994;19-20: 519-61.
6. Munoz H, Bosch FX HPV and cervical neoplasia: review of case-control and cohort studies. IARC Sci Publ 1992;(l 19):251-6 1.
7. Chichareon S. Cervical cancer incidence in the South of Thailand 1988-1989. J Med Assoc Thai 1993;76:146-51.
8. Robles SC, White F, Peruga A. Trends in cervical cancer mortality in the Americas. Bull Pan Am Health Organ 1996;30:290-301.
9. Hakama M, Miller AB, Day NE. Screening for cancer of the uterine cervix. IARC Sci Publ 1986;76:161-8.
10. Womack SD, Chirenje ZM, Blumenthal PD, Gaffikin L, McGrath JA, Chipato T, et al. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. BJOG 2000;107:33-8.
11. Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papillo mavirus testing be used to improve cervical cancer screening? Int J Cancer 1996;65:768-73.
12. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818-25.
13. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Braid M, Wacholder S, et al. HPV DNA testing in cervical cancer screening. JAMA 2000;283:87-93.
14. Ferrera A, Velema JP, Figueroa M, Bulnes R, Toro LA, Claros JM, et al. Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: a case-control study. Int J Cancer 1999;82:799-803.
15. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74.
16. Chichareon S, Herrero R, Munoz N, Bosch FX, Jacobs MV, Deacon J, et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst 1998;90:50-7.
17. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz, A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-6.
18. Ratman S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945-51.
19. Sankaranarayanan R, Wesley R, Somanathan T, Dhakad N, Shyamalakumary B, Amma NS, et al. Visual inspection of the uterine cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors. Cancer 1998;83:2150-6.
20. Sankaranarayanan R, Shyamalakumary B, Wesley R, Sreedevi Amma N, Parkin DM, Nair MK. Visual inspection with acetic acid in the early detection of cervical cancer and precursors. Int J Cancer 1999;80:161-3.
21. Van LL, Broekhuizen FF, Janzer-Steele R, Behar M, Samter T. Acetic acid visualization of the cervix to detect cervical dysplasia. Obstet Gynecol 1993;81:293-5.
22. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Lancet 1999;353:869-73.
23. Vatanasapt V, Sriampom S, Kamsaard S, Suwanrungruang K, Pengsaa P, Charoensiri DJ, et al. Cancer survival in Khon Kaen, Thailand. IARC Sci Publ 1998; 145:123-34.
24. Vatanasapt V, Martin N, Sriplung H, Chindavijak K, Sontipong S, Sriampom H, et al. Cancer incidence in Thailand, 1988-1991. Cancer Epidemiol Biomarkers Prev 1995;4:475-83.
25. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carol simulation. A practical approach. Med Decis Making 1985;5:157-77.
26. Bunnell RE, Yanpaisarn S, Kilmarx PH, Rhodes PH, Limpakarnjanarat K, Srismith R, et al. HIV-1 seroprevalence among childbearing women in northern Thailand: monitoring a rapidly evolving epidemic. AIDS 1999; 13:509-15.
27. Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999;130:97-107.
28. Mandelblatt JS, Gold K, O'Malley AS, Taylor K, Cagney K, Hopkins JS, et al. Breast and cervix cancer screening among multiethnic women: role of age, health, and source of care. Prev Med 1999;28:418-25.
29. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancer in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-10.
30. Gold M, Seigel J, Weinstein M, Russell L, eds. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 1996.
31. Limpaphayom KK, Lumbiganon P, Gaffikin L, Worakamin S, Srisupundit S, Ringers P, et al. Safety and acceptability of visual inspection using acetic acid (VIA) and cryotherapy for cervical cancer prevention in Roi-et Province, Thailand. Australia and New Zealand Society of Obstetrics and Gynaecology, Annual Meeting. 2001 Oct 22: Sydney (Australia).
32. Kiviat N. Natural history of cervical neoplasia: overview and update. Am J Obstet Gynecol 1996;175:1099-104.
33. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
34. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidermiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-.64.
35. Shah KV, Kessis TD, Shah F, Gupta JW, Shibata D, Jones RW. Human papillomavirus investigation of patients with cervical intraepithelial neoplasia 3, some of whom progressed to invasive cancer. Int J Gynecol Pathol 1996;15:127-30.
36. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
37. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
38. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-58.
39. Mandelblatt JS, Fryback D, Weinstein MC, Russell LB, Gold MR. Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med 1997;12:551-8.
40. Ekalaksananan T, Pientong C, Kotimanusvanij D, Kongyingyoes B, Sriamporn S, Jintakanon D. The relationship of human papillomavirus (HPV) detection to pap smear classification of cervical-scraped cells in asymptomatic women in northeast Thailand. J Obstet Gynaecol Res 2001;27:117-24.
41. Sukvirach S, Walboomers JM, Meijer CJ, Munoz N, Herrero R. HPV infection in a population sample of women in Lampang, Thailand. Abstract presented at Barcelona HPV Meeting, Summer, 2000.
42. McCrory DC, Thatcher DB, Bastian L, et al. Evaluation of cervical cytology, evidence report/technology assessment No. 5. Agency for Health Care Policy and Research, Rockville, MD 1999; (February). Office of Technology Assessment-Special Report.
43. Nobbenhuis M, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
44. Brisson J, Bairati I, Morin C, Fortier M, Bouchard C, Christen A, et al. Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis 1996;173:794-9.
45. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 1996;69:364-8.
46. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
47. Moscicki AB, Palefsky J, Sntith G, Siboshski S, Shoolnik G. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstet Gynecol 1993;82:578-85.
48. Sherlaw-Johnson C, Gallivan S, Jenkins D. Evaluating cervical cancer screening programmes for developing countries. Int J Cancer 1997;72:210-6.
49. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986;67:665-9.
50. Holowaty P, Miller AB, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8.
51. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132:277-84.
52. Gaarenstroom KN, Melkert P, Walboomers JM, Van Den Brule AJ, Van Bommel PF, Meyer CJ, et al. Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer 1994;4:73-8.
53. Nuovo G, Moritz J, Kowalik A, Chalas E, Kaplan B, Mann W. Human papillomavirus types and cervical squamous intraepithelial lesions that recur after cold-knife conization. Gynecol Oncol 1992;46:304-8.
54. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
55. Liaw KL, Glass AG, Manus MM, Greer CE, Scott DR, Sherman M, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-60.
56. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, et al. The presence of persistent high-risk HPV genotype in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
57. Van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991; 64:559-65.
58. Kataja V, Syrjanen K, Syrjanen S, Mantyjarvi R, Yliskoski M, Saarikoski S, et al. Prospective follow-up of genital HPV infections: survival analysis of the HPV typing data. Eur J Epidemiol 1990;6:9-14.
59. Meijer CJ, van den Brule AJ, Snijders PJ, Helmerhorst T, Kenemans P, Walboomers JM. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Sci Publ 1992;(l 19):271-8 1.
60. Londhe M, George SS, Seshadri L. Detection of CIN by naked eye visualization after application of acetic acid. Indian J Cancer 1997;34:88-91.
61. Kesic VI, Soutter WP, Sulovic V, Juznic N, Aleksic M, Ljubic A. A comparison of cytology and cervicography in cervical screening. Int J Gynecol Cancer 1993;3:395-8.
62. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;91:626-31.
63. Ottaviano, M, La Torte P. Examination of the cervix with the naked eye using acetic test. Am J Obstet Gynecol 1982;143:139-42.
64. Bishop A, Sherris J, Tsu VD, Kilbourne-Brook M. Cervical dysplasia treatment: key issues for developing countries. Bull Pan Am Health Organ 1996;30:378-86.
65. Benedet JL, Miller DM, Nickerson KG, Anderson GH. The results of cryosurgical treatment of cervical intraepithelial neoplasia at one, five, and ten years. Am J Obstet Gynecol 1987;157:268-73.
66. Benedet JL, Miller DM, Nickerson KG. Results of conservation management of cervical intraepithelial neoplasia. Obstet Gynecol 1992;79: 105-10.
67. Santos C, Galdos R, Alvarez M, Velarde C, Barriga 0, Dyer R, et al. One-session management of cervical intraepithelial neoplasia: a solution for developing countries. Gynecol Oncol 1996;61:11-5.
68. Holschneider CH, Ghosh K, Montz FJ. See-and-treat in the management of high grade squamous intraepithelial lesions of the cervix: a resource utilization analysis. Obstet Gynecol 1999;94:377-85.
69. Ministry of Public Health. Public Health Statistics AD 1996. 1996. Thailand.
70. Myers ER, McCrory DC, Nanda K, Bastian L, Mathcar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71.
71. Coppleson LW, Brown B. Observations on a model of the biology of carcinoma of the cervix: a poor fit between observation and theory. Am J Obstet Gynecol 1975;122:127-36.
72. Boyes DA, Morrison B, Knox EG, Draper GJ, Miller AB. A cohort study of cervical cancer screening in British Columbia. Clin Invest Med 1982; 5:1-29.
73. van Ballegooijen M, van den Akker-van Marle ME, Warmerdam. PG, Meijer CJ, Walboomers JM, Habbema JD. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. Br J Cancer 1997;76:651-7.
74. Schiffman MH, Schatzkin A. Test reliability is critically important to molecular epidemiology: an example from studies of human papillomavirus infection and cervical neoplasia. Cancer Res 1994;54(7 Suppl): 1944s-1947s.
75. Schiffman MH, Kiviat NB, Burk RD, Shah KV, Daniel RW, Lewis R, et al. Accuracy and inter-laboratory reliability of human papillomavirus DNA testing by hybrid capture. J Clin Microbiol 1995;33:545-50.
76. Sigurdsson K, Arnadottir T, Snorradottir M, Benediktsdottir K, Saemundsson H. Human papillomavirus (HPV) in an Icelandic population: the role of HPV DNA testing based on hybrid capture and PCR assays among women with screen-detected abnormal pap smears. Int J Cancer 1997;72:446-52.
77. Fahey MT, Irwig L, Macaskill. P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:680-9.
78. Mandelblatt J, Yabroff KR. Breast and cervical cancer screening for older women: recommendations and challenges for the 2lst century. J Am Med Womens Assoc 2000;55:210-5.
79. Mandelblatt J, Gopaul I, Wistreich M. Gynecological care of elderly women: another look at Papanicolaou smear testing. JAMA 1986;256: 367-71.
80. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-9.
81. Lorincz AT. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J Obstet Gynaecol Res 1996;22:629-36.
82. Lorincz AT. Molecular methods for the detection of human papillomavirus infection. Obstet Gynecol Clin North Am 1996;23:707-30.
83. Control of cancer of the cervix uteri. A WHO meeting. Bull World Health Organ 1986;64:607-18.
84. Kashimura M, Taki I. Cryosurgery for dysplasia, carcinoma in situ, and microinvasive carcinoma of the uterine cervix (author's transl). Acta Obstet Gynaecol Jpn 1981;33:635-42.
85. Harper DM, Mayeaux EJ, Daaleman TP, Woodward LD, Ferris DG, Johnson CA. The natural history of cervical cryosurgical healing. The minimal effect of debridement of the cervical eschar. J Fam Pract 2000;49:707-8.
86. Blumenthal PD, Gaffikin L, Mandelblatt J. Low technology options for cervical cancer screening. 18th International Papillomavirus Conference. 2000. Barcelona, Spain.
87. Society of Gynecologic Oncologists Medical Practice and Ethics Committee. Clinical practice guidelines: management of gynecologic cancers. Chicago (IL): Society of Gynecologic Oncologists; 1996.
88. Tay EH, Yeap ML, Ho TL. A 5-year review of FIGO stage IB cervical cancer in an Asian population. Singapore Med J 1997;38:520-4.
89. Srisupundit S, Kraiphibul P, Tangtrakul S, Bhamarapravati Y. Cervical cancer survival at Ramathibodi Hospital 1979-1983. J Med Assoc Thai 1990;73 Suppl 1:15-9.
90. Pengsaa P, Pesi M, Udomthavomsuk B, Tungvorapongchai V, Vatanasapt W, Shibata Y. Survival analysis of cervical cancer patients at Srinagarind Hospital 1976-1987. J Med Assoc Thai 1989;72:346-50.
91. Vatanasapt V, Sriamporn S, Kamsaard S, Suwanrungruang K, Pengsaa P, Charoensiri DJ, et al. Cancer survival in Khon Kaen, Thailand. IARC Sci Publ 1998;(145):123-34.
92. Pengsaa P, Vatanasapt V, Sri-Amporn S, Udomthavomsuk B. Cervical cancer in Khon Khaen University Hospital, Thailand 1985-1990. Eur J Gynaecol Oncol 1993;14:331-5.
93. Jayaraman K, Nene BM, Dinshaw KA, Budukh AM, Dale PS. Survival from cervical cancer in Barshi registry, rural India. 1998.
94. Nandakumar A, Anantha N, Venugopal TC. Population-based survival from breast and cervical cancer and lymphoreticular malignancies in Bangalore, India. IARC Sci Publ 1998;(145):61-8.
95. Gold MR, Franks P, McCoy K, Fryback D. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998;36:778-92.
96. Moritz FJ. Impact of therapy for cervical intraepithelial neoplasia on fertility. Am J Obstet Gynecol 1996;175(4 Pt 2):1129-36.
97. Benrubi GI, Young M, Nuss RC. Intrapatum outcome of term pregnancy after cervical cryotherapy. J Reprod Med 1984;29:251-4.
98. The Bank of Thailand. Average wage classified by industry, and employees for the whole kingdom. 2000. [Last accessed: 7/15/2001.] Available at: www.bot.or.th/research/public/sdds/stat5/wage99.htm.
99. The World Bank Thailand office. Thailand Economic Monitors. 2000. [Last accessed: 7/15/2001.] Available at: www.worldbank.or.th/economic/ index.html.
100. Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton (FL): Chapman & Hall/CRC; 1998.
101. Hunink MG, Bult JR, de Vries J, Weinstein MC. Uncertainty in decision modeling analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998;18:337-46.
102. Goldie S, Kuhn L, Denny L, Pollack A, Wright T. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107-15.
103. Kitchener HC, Symonds P. Detection of cervical intraepithelial neoplasia in developing countries. Lancet 1999;353:856-7.
104. Megevand E, Van Wyk W, Knight B, Bloch B. Can cervical cancer be prevented by a see, screen, and treat program? A pilot study. Am J Obstet Gynecol 1996;174:923-8.
105. Serwadda D, Wawer MJ, Shah KV, Sewankambo NK, Daniel R, Li C, et al. Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. J Infect Dis 1999;180: 1316-9.
106. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specifc human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer 1994;69:167-71.
107. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer 2000;83:561-5.
108. Suba EJ, Hung NC, Duc NB, Raab SS. De novo establishment and cost-ffectiveness of Papanicolaou cytology screening services in the socialist republic of Vietnam. Cancer 2001;91:928-39.
109. Boer R, Ballegooijen M van, Meerding WJ, Singh V, Sehgal A, Habbema JDF. Unaided visual examination of the cervix versus pap-smears for early detection of cervical cancer. 4th International Multidisciplinary Congress Eurogin, 2000.
110. Xuan LV, Giang LT, Man PD, Truc NQ, Quoc NM, Trung NS, et al. The establishment and cost effectiveness of pap smear screening services in a developing country. The Viet/American Cervical Cancer Prevention Project 1999; 88th Annual Meeting of the United States and Canadian Academy of Pathology, 1999 March 21; San Francisco (CA).
111. Swaddiwudhipong W, Chaovakiratipong C, Nguntra P, Mahasakpan P, Tatip Y, Boorimak C. A mobile unit; an effective service for cervical cancer screening among rural Thai women. Int J Epidemiol 1999;28:35-9.
112. Koopmanschap MA, van Oortmarssen GJ, van Agt HM, Ballegooijen M, Habbema JD, Lubbe K. Cervical-cancer screening: attendance and cost-effectiveness. Int J Cancer 1990;45:410-5.
113. Fahs M, Mandelblatt J, Schechter C, Muller C. Cost effectiveness of cervical cancer screening. Ann Intern Med 1992; 117:520-7.
114. Alberg AJ, Selhub J, Shah KV, Viscidi RP, Comstock GW, Helzlsouer KJ. The risk of cervical cancer in relation to serum concentrations of folate, vitamin B12, and homocysteine. Cancer Epidemiol Biomarkers Prev 2000;9:761-4.
115. Vancenwyk J, Davis FG, Colman N. Folate, vitamin C, and cervical intra-epithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1992; 1: 119-24.
116. Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA 1999;281:347-53.
117. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-10.
118. Jenkins D, Sherlaw-Johnson C, Gallivan S. Assessing the role of HPV testing in cervical cancer screening. Papillomavirus Report 1998;9:89-101.
119. Hristova L, Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol 1997;36:1-60.
120. Eddy DM, editor. Common screening tests. Cervical cancer screening. Philadelphia (PA): American College of Physicians; 1991.
121. Sankaranayanan R. Integration of cost-effective early detection programs into the health services of developing countries. Cancer 2000;89:475-81.